Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:5940 |
Name | malignant peripheral nerve sheath tumor |
Definition | |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer nervous system cancer peripheral nervous system neoplasm peripheral nerve sheath neoplasm malignant peripheral nerve sheath tumor |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02275286 | Phase Ib/II | Trabectedin | Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients (TRASTS) | Unknown status | ITA | FRA | ESP | 0 |
NCT02301039 | Phase II | Pembrolizumab | A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas | Completed | USA | 0 |
NCT02372006 | Phase Ib/II | Afatinib | Trial of Afatinib in Pediatric Tumours | Completed | USA | ITA | FRA | ESP | DEU | CAN | AUT | 5 |
NCT02584309 | Phase II | Dexrazoxane Doxorubicin + Olaratumab | Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma | Active, not recruiting | USA | 0 |
NCT02584647 | Phase Ib/II | Pexidartinib + Sirolimus | Combination of PLX3397 and Sirolimus in Unresectable Sarcoma (Phase 1) and Malignant Peripheral Nerve Sheath Tumors (Phase 2) | Recruiting | USA | 0 |
NCT02601209 | Phase Ib/II | Pazopanib Sapanisertib | Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma | Active, not recruiting | USA | 0 |
NCT02639546 | Phase Ib/II | Cobimetinib | Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors (iMATRIXcobi) | Completed | USA | ITA | FRA | ESP | DEU | 2 |
NCT02700230 | Phase I | MV-NIS | Vaccine Therapy in Treating Patients With Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by Surgery | Recruiting | USA | 0 |
NCT02978859 | Phase II | Sitravatinib | MGCD516 in Advanced Liposarcoma and Other Soft Tissue Sarcomas | Active, not recruiting | USA | 0 |
NCT02986919 | Phase II | CPI-0610 | Study of CPI-0610 in Patients With Malignant Peripheral Nerve Sheath Tumors | Withdrawn | USA | 0 |
NCT02987959 | Phase II | Sapanisertib | Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas | Terminated | USA | 0 |
NCT03009201 | Phase I | Doxorubicin + Ribociclib | Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery | Active, not recruiting | USA | 0 |
NCT03433183 | Phase II | Selumetinib + Sirolimus | SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors | Active, not recruiting | USA | 0 |
NCT03611868 | Phase Ib/II | APG-115 + Pembrolizumab | A Study of APG-115 in Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors | Recruiting | USA | 1 |
NCT03872427 | Phase II | Telaglenastat | Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study | Active, not recruiting | USA | 0 |
NCT03880123 | Phase I | Ixazomib + Selinexor | Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma | Withdrawn | USA | 0 |
NCT04028063 | Phase II | Balstilimab + Doxorubicin + Zalifrelimab | Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas | Active, not recruiting | USA | 0 |
NCT04216953 | Phase Ib/II | Atezolizumab + Cobimetinib | MEK Inhibitor and a PDL1 Inhibitor Patients With Locally Advanced and/or Metastatic Soft Tissue Sarcoma (COTESARC) | Recruiting | FRA | 0 |
NCT04465643 | Phase I | Ipilimumab + Nivolumab | Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor | Recruiting | USA | 0 |
NCT04741438 | Phase III | Ipilimumab + Nivolumab Pazopanib | Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare Subtype (RAR-Immune) | Recruiting | FRA | 0 |
NCT04784247 | Phase II | Lenvatinib + Pembrolizumab | Lenvatinib and Pembrolizumab in People With Advanced Soft Tissue Sarcoma | Recruiting | USA | 0 |
NCT04811196 | Phase I | Selinexor | A Study of Different Dosing Schedules of Selinexor in Sarcoma Patients | Recruiting | CAN | 0 |
NCT04872543 | Phase II | Decitabine and Cedazuridine | A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST) | Recruiting | USA | 0 |
NCT04917042 | Phase II | Tazemetostat | Tazemetostat in Malignant Peripheral Nerve Sheath Tumors | Recruiting | USA | 0 |
NCT05253131 | Phase Ib/II | AZD5153 + Durvalumab + Selumetinib AZD5153 + Selumetinib | Trial of Selumetinib and AZD5153 With Durvalumab for Sarcomas | Not yet recruiting | USA | 0 |